Table 2.

HR and 95% CI for the association between changes in TyG index from 2006 to 2010 and cardiovascular diseases and its subtypes

	Quartiles of changes in TyG index				P for trend
	Q1 (< − 0.31)	Q2 (− 0.31 to 0.05)	Q3 (0.05–0.41)	Q4 (≥ 0.41)
CVD
Case, n (%)	585 (3.75)	594 (3.81)	646 (4.14)	705 (4.52)
Incidence rate, per 1000 person-y	5.54 (5.11–6.01)	5.65 (5.21–6.12)	6.17 (5.71–6.66)	6.73 (6.25–7.24)
Model 1	Reference	1.18 (1.06–1.32)	1.26 (1.12–1.42)	1.42 (1.26–1.60)	< 0.0001
Model 2	Reference	1.17 (1.04–1.30)	1.24 (1.11–1.40)	1.37 (1.21–1.54)	< 0.0001
Stroke
Case, n (%)	465 (2.98)	473 (3.03)	528 (3.38)	552 (3.54)
Incidence rate, per 1000 person-y	4.39 (4.01–4.80)	4.48 (4.10–4.91)	5.03 (4.62–5.47)	5.24 (4.82–5.70)
Model 1	Reference	1.24 (1.08–1.41)	1.27 (1.11–1.47)	1.44 (1.24–1.66)	< 0.0001
Model 2	Reference	1.22 (1.07–1.40)	1.26 (1.09–1.45)	1.38 (1.19–1.60)	< 0.0001
MI
Case, n (%)	126 (0.81)	126 (0.81)	128 (0.82)	165 (1.06)
Incidence rate, per 1000 person-y	1.18 (0.99–1.40)	1.19 (1.00–1.41)	1.21 (1.02–1.44)	1.55 (1.33–1.81)
Model 1	Reference	1.05 (0.82–1.34)	1.22 (0.95–1.57)	1.41 (1.09–1.82)	0.0050
Model 2	Reference	1.02 (0.80–1.30)	1.19 (0.93–1.53)	1.36 (1.05–1.76)	0.0115

Model 1: adjusted for age, sex, and TyG index at baseline. Model 2: further adjusted for education, income, smoking status, drinking status, physical activity, body mass index, systolic blood pressure, diastolic blood pressure, a history of hypertension, diabetes mellitus, and dyslipidemia, antidiabetic agents, lipid-lowering agents, antihypertensive agents, high-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein at baseline

CI confidence interval, CVD cardiovascular disease, MI mypcardial infarction, HR hazard ratio, TyG index triglyceride-glucose index